Neovacs SA (FR:ALNEV) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neovacs SA, a French biotech firm specializing in inflammatory and autoimmune therapies, has disclosed its share capital composition, revealing a total of 347,174,292 shares and equal voting rights as of August 31, 2024. The company has undergone a share consolidation and issues monthly reports on new share creation, including conversions of OCEANE bonds and exercises of BSA E, with detailed updates available on its website. However, the company warns of potential share price volatility and investor dilution due to the rapid sale of shares by the European High Growth Opportunities Securitization Fund and a trust responsible for the equitization of ORA financing.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.